Pharmacokinetic study of imrecoxib in patients with renal insufficiency.

Abstract

OBJECTIVE:

Renal insufficiency may influence the pharmacokinetics of drugs. We have investigated the pharmacokinetic parameters of imrecoxib and its two main metabolites in individuals with osteoarthritis (OA) with normal renal function and renal insufficiency, respectively.

METHODS:

This was a prospective, parallel, open, matched-group study in which 24 subjects were enrolled (renal insufficiency group, n = 12; healthy control group, n = 12). Blood samples of subjects administered 100 mg imrecoxib were collected at different time points and analyzed. Plasma concentrations of imrecoxib and its two metabolites (M1 and M2) were determined by the liquid chromatography-tandem mass spectrometry method, and pharmacokinetic parameters (clearance [CL], apparent volume of distribution [Vd], maximum (or peak) serum concentration [Cmax], amount of time drug is present in serum at Cmax [Tmax], area under the curve [AUC; total drug exposure across time], mean residence time [MRT] and elimination half-life [t1/2]) were calculated.

RESULTS:

The demographic characteristics of the two groups were not significantly different, with the exception of renal function. The mean Cmax and AUC0-t (AUC from time 0 to the last measurable concentration) of imrecoxib in the renal insufficiency group were 59 and 70%, respectively, of those of the healthy control volunteers with normal renal function, indicating a significant decline in the former group (P < 0. 05). The mean pharmacokinetic parameters of Ml in the renal insufficiency and healthy control groups did not significantly differ. In contrast, the mean Cmax and AUC0-t of M2 in the renal insufficiency group were 233 and 367%, respectively, of those of the normal renal function group, indicating a significant increase in the former group (P < 0.05). The mean CL/F (clearance/bioavailability) of M2 of the renal insufficiency group was 37% of that of the normal renal function group, indicating a notable reduction in the former group (P < 0.05).

CONCLUSION:

The exposure of imrecoxib in OA patients with renal insufficiency showed a decline compared to that in healthy subjects. However, in patients with renal insufficiency the exposure of M2 was markedly increased and the CL was noticeably reduced. These results indicate that the dosage of imrecoxib should be reduced appropriately in patients with renal insufficiency.

• Authors: Qi Pei, Jin-Lian Xie, Jie Huang, Wen-Yu Liu, Xiao-Yan Yang, Yan Wang, Wei Li, Hong-Yi Tan, Hao Zhang, Guo-Ping Yang
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 75 Issue 10 Pg. 1355-1360 (Oct 2019) ISSN: 1432-1041 [Electronic] Germany
• PMID: 31243478 (Publication Type: Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article)

Chemical References

• Cyclooxygenase 2 Inhibitors
• Imrecoxib
• Pyrroles
• Sulfides

Topics

• Adult
• Aged
• Cyclooxygenase 2 Inhibitors (blood, pharmacokinetics, therapeutic use)
• Drug Interactions
• Female
• Humans
• Male
• Middle Aged
• Osteoarthritis (drug therapy, metabolism)
• Pyrroles (blood, pharmacokinetics, therapeutic use)
• Renal Insufficiency (drug therapy, metabolism)
• Sulfides (blood, pharmacokinetics, therapeutic use)